Solventum (NYSE:SOLV) Raised to “Strong-Buy” at Zacks Research

Solventum (NYSE:SOLV – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday, Zacks reports.

A number of other analysts have also recently weighed in on SOLV. Wedbush raised their price objective on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $113.00 target price on Solventum in a research note on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Wells Fargo & Company increased their price target on Solventum from $89.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. Finally, Benchmark reiterated a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $90.27.

Read Our Latest Stock Report on Solventum

Solventum Stock Up 0.0%

SOLV traded up $0.04 during trading on Thursday, hitting $88.85. The stock had a trading volume of 917,954 shares, compared to its average volume of 1,291,136. The company has a market capitalization of $15.08 billion, a PE ratio of 99.83, a PEG ratio of 1.26 and a beta of 0.69. Solventum has a twelve month low of $62.38 and a twelve month high of $94.16. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03. The stock has a 50 day simple moving average of $87.53 and a two-hundred day simple moving average of $78.95.

Solventum (NYSE:SOLV – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.50 earnings per share. On average, research analysts predict that Solventum will post 7.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SOLV. North Dakota State Investment Board grew its holdings in shares of Solventum by 3.1% during the third quarter. North Dakota State Investment Board now owns 4,525 shares of the company’s stock worth $399,000 after buying an additional 134 shares in the last quarter. IFP Advisors Inc raised its position in shares of Solventum by 12.7% in the third quarter. IFP Advisors Inc now owns 1,211 shares of the company’s stock valued at $107,000 after buying an additional 136 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock worth $438,000 after buying an additional 144 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in shares of Solventum by 3.2% in the third quarter. Diversify Advisory Services LLC now owns 5,000 shares of the company’s stock worth $439,000 after buying an additional 153 shares in the last quarter. Finally, Empirical Finance LLC boosted its position in Solventum by 3.6% during the second quarter. Empirical Finance LLC now owns 5,074 shares of the company’s stock worth $391,000 after acquiring an additional 174 shares during the last quarter.

Solventum Company Profile

(Get Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Further Reading

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.